Smith G W, Bukowski R M, Hewlett J S, Groppe C W
Cancer. 1984 Oct 15;54(8):1513-6. doi: 10.1002/1097-0142(19841015)54:8<1513::aid-cncr2820540806>3.0.co;2-9.
Eleven patients with histologically proven cholangiocarcinoma and gallbladder carcinoma were treated with hepatic artery infusion (HAI) of 5-fluorouracil (5-FU) and mitomycin C (Mito-C). Catheters were placed percutaneously through the femoral artery. The schedule used was 5-FU 1200/mg/m2/day given as a continuous infusion for 4 days, plus Mito-C 6 mg/m2 on days 1 and 4. Courses were repeated every 4 weeks. Complete responses (CR) occurred in one patient (9%), and partial response (PR) occurred in six patients (55%). Median survival for all patients from the start of the first treatment was 12.5+ months. Median duration of the response was 3.0 months. Median survival of the patients with gallbladder carcinoma was 12.5 months, and for patients with cholangiocarcinoma has not yet been reached. Drug toxicity was mild, and morbidity of the HAI was minimal. Further trials of chemotherapy in these two neoplasms are warranted.
11例经组织学证实的胆管癌和胆囊癌患者接受了肝动脉灌注(HAI)5-氟尿嘧啶(5-FU)和丝裂霉素C(丝裂霉素C)治疗。通过股动脉经皮放置导管。使用的方案是5-FU 1200/mg/m²/天持续输注4天,加丝裂霉素C 6 mg/m²在第1天和第4天使用。每4周重复疗程。1例患者(9%)出现完全缓解(CR),6例患者(55%)出现部分缓解(PR)。所有患者从首次治疗开始的中位生存期为12.5+个月。缓解的中位持续时间为3.0个月。胆囊癌患者的中位生存期为12.5个月,胆管癌患者的中位生存期尚未达到。药物毒性轻微,肝动脉灌注的发病率极低。对这两种肿瘤进行进一步的化疗试验是必要的。